FSSAI acts against British Life Sciences over infant-food violations in Bengaluru

FSSAI seized misbranded infant food, initiated legal action and destroyed 3.7 metric tonnes of expired stock linked to Bengaluru-based British Life Sciences. The regulator has also proposed front-of-pack red-hexagon warnings for packaged foods high in fat, sugar or salt.

— Source publishedThu, 3 Sept, 2026, 12:51 IST·First seen Thu, 3 Sept, 2026, 12:52 IST·Source Outlook Business

What happened

FSSAI seized misbranded infant food from British Life Sciences in Bengaluru, began legal action and destroyed 3.7 tonnes of expired stock. Separately, it

Key facts

  • 3.7 metric tonnes
  • Food Safety and Standards Act, 2006
  • 2017

Why this matters

Build regulatory diligence around labelling accuracy, quality systems and ageing inventory into FMCG deal screens, with infant nutrition requiring heightened scrutiny.

What to watch

  • FSSAI notices, product recalls or license suspensions involving additional infant-nutrition companies.
  • Formal notification, final design rules or implementation dates for red-hexagon front-of-pack warnings.
  • State-level inspection drives targeting pharmacies, modern trade warehouses, e-commerce sellers or distributors.
  • British Life Sciences legal filings, distributor delistings, retailer returns or evidence of broader batch exposure.
  • Higher retailer demands for shelf-life thresholds, lab reports, traceability data and supplier penalties.
  • Audit expiry controls, batch traceability, label approvals and distributor-held inventory, with infant nutrition prioritized.
  • Quarantine and independently test high-risk or slow-moving infant-food stock before regulator inspections force write-offs.
  • Build a compliance roadmap for potential front-of-pack nutrient warnings, including SKU-level nutrition mapping and reformulation options.
  • Retailers and marketplaces should tighten supplier indemnities, require current FSSAI documentation and improve recall-notification workflows.
  • Competitors should prepare trust-led communications around quality assurance, pediatric appropriateness and transparent ingredient disclosure.